Immune checkpoint inhibitors combined with chemotherapy enhance coagulation activation and elevate venous thromboembolism risk in non-small cell lung cancer
American Journal of Cancer Research · 2026 · 16 (1) · 338-352
DOI: 10.62347/fygp7808 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Cancer Research, 2026. Verfasst von Weihua Song und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Nantong First People's Hospital Nantong 226001, Jiangsu, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Thromboseprophylaxe, Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Laboratory, Nantong First People's Hospital Nantong 226001, Jiangsu, China.
- Department of Oncology, Nantong First People's Hospital Nantong 226001, Jiangsu, China.
Zitieren
APA
Song, W., Chu, F., Xie, W., Zhao, P., Miao, Y., & Chen, X. (2026). Immune checkpoint inhibitors combined with chemotherapy enhance coagulation activation and elevate venous thromboembolism risk in non-small cell lung cancer. American Journal of Cancer Research, 16(1), 338-352. https://doi.org/10.62347/fygp7808
Vancouver
Song W, Chu F, Xie W, Zhao P, Miao Y, Chen X. Immune checkpoint inhibitors combined with chemotherapy enhance coagulation activation and elevate venous thromboembolism risk in non-small cell lung cancer. American Journal of Cancer Research. 2026;16(1):338-352. doi:10.62347/fygp7808
BibTeX
@article{Song2026,
author = {Song, Weihua and Chu, Fuying and Xie, Wei and Zhao, Ping and Miao, Yajun and Chen, Xiang},
title = {Immune checkpoint inhibitors combined with chemotherapy enhance coagulation activation and elevate venous thromboembolism risk in non-small cell lung cancer},
journal = {American Journal of Cancer Research},
year = {2026},
volume = {16},
number = {1},
pages = {338--352},
doi = {10.62347/fygp7808}
}
EUVIMED